Show simple item record

dc.contributor.authorBigham, Mark
dc.contributor.authorKonrad, Stephanie
dc.contributor.authorVan Buynder, Paul
dc.contributor.authorVan Buynder, Jan
dc.contributor.authorIsaac-Renton, Judy
dc.contributor.authorElSherif, May
dc.contributor.authorHalperin, Scott A
dc.date.accessioned2018-12-03T03:20:51Z
dc.date.available2018-12-03T03:20:51Z
dc.date.issued2014
dc.identifier.issn0264-410X
dc.identifier.doi10.1016/j.vaccine.2014.09.028
dc.identifier.urihttp://hdl.handle.net/10072/173518
dc.description.abstractInfants under 6 months of age are at greatest risk of mortality and severe morbidity from pertussis disease. Interventions that increase pertussis protection in newborns are therefore a clear public health imperative. The objective of this study was to assess maternal pertussis toxin antibody (anti-PT) level as a potential source of mother-to-child transfer of pertussis-associated antibodies that may reduce neonatal risk of pertussis disease. Anti-PT level was assessed in a 2013 cohort of pregnant women from two regions in two Canadian provinces, British Columbia and Nova Scotia. Basic demographics, health, and pertussis immunization history were collected, along with blood specimens. Anti-PT levels were compared for self-reported vaccination status and prior pertussis disease. To assess secular trend, a parallel analysis was also undertaken, using anonymized residual sera from a 1996–1997 cohort of pregnant women in British Columbia. A total of 169 pregnant women participated in the study – 50 from Nova Scotia and 119 from British Columbia. The mean and median age of participants from both sites was 31 years of age (range 16–42 years). The lower limit of quantification of the anti-PT assay was 10 ELISA units per milliliter (EU/ml). Overall, 59% of women had anti-PT levels less than 10 EU/ml and anti-PT level did not differ with time since last self-reported pertussis vaccination (χ2(2) = 3.166, p = 0.205). Among a 1996–1997 cohort of pregnant women in British Columbia, 101 of 200 (51%) had anti-PT levels less than 10 EU/ml. Our study found that most pregnant women in two geographically disparate health regions in Canada have low residual anti-PT levels, may be vulnerable to pertussis infection themselves, and would unlikely be a source of passive ante- or postnatal transfer of anti-PT to their newborn.
dc.description.peerreviewedYes
dc.languageEnglish
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofpagefrom6493
dc.relation.ispartofpageto6498
dc.relation.ispartofissue48
dc.relation.ispartofjournalVaccine
dc.relation.ispartofvolume32
dc.subject.fieldofresearchEpidemiology
dc.subject.fieldofresearchBiological Sciences
dc.subject.fieldofresearchAgricultural and Veterinary Sciences
dc.subject.fieldofresearchMedical and Health Sciences
dc.subject.fieldofresearchcode111706
dc.subject.fieldofresearchcode06
dc.subject.fieldofresearchcode07
dc.subject.fieldofresearchcode11
dc.titleLow pertussis toxin antibody levels in two regional cohorts of Canadian pregnant women
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
gro.hasfulltextNo Full Text
gro.griffith.authorVan Buynder, Paul G.


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record